CAR-T cell therapy cost in Thailand

CAR-T cell therapy cost in Thailand by product access, eligibility, and intensive-care risk

CAR-T is a highly specialized cellular treatment, not a routine infusion that every hospital can provide. A Thailand plan must identify the cancer indication, prior lines, remission status, product or clinical-trial route, manufacturing location, leukapheresis, bridging therapy, lymphodepletion, cell infusion, monitoring, cytokine-release and neurologic toxicity response, ICU, infection prevention, caregiver, and long follow-up. Official Thai sources describe research and specialist cellular-therapy development; availability, registration, and trial enrollment must be confirmed directly with the named center.

How much does CAR-T cell therapy cost in Thailand?

Evaluation and leukapheresis planning in Thailand may be budgeted at THB 990,000 to 2,310,000, approximately USD 30,000 to 70,000, before a full cellular product is available. A complete commercial or approved program, where the product and center are accessible, may fall around THB 4,950,000 to 9,900,000, about USD 150,000 to 300,000. Bridging treatment, prolonged admission, ICU, infection, cytokine-release syndrome, neurotoxicity, or other complications can push a complex journey to THB 9,900,000 to 19,800,000+, approximately USD 300,000 to 600,000+. These are broad planning ranges, not a promise that a commercial CAR-T product is available in Thailand.

USD illustrations use approximately THB 33 per USD, based on the Bank of Thailand exchange-rate context checked in July 2026. Cellular products and hospital services can be quoted in THB or foreign currency. Confirm manufacturing, product, deposit, cancellation, failed-manufacture, ICU, and exchange-rate terms in writing.

Review cost scenarios Upload reports

Let Us Help You

Share the basics and the Virello team will guide you toward the next step.

Prefer email? Write to support@virellohealth.com.

Patient Name

Country

Phone Number

Describe The Current Medical Problem

Reviewed 2026-07-19

Clinical review: Virello Health Clinical Content Team · Editorial review: Virello Health Research Team

Billing context: THB and USD

Thailand access is center-specific

A government article about CAR-T development or a hospital cellular-therapy page does not mean every patient can buy an approved commercial product.

Eligibility is narrow

Cancer type, antigen, prior treatment, performance status, disease burden, organ function, infection, and trial criteria determine entry.

Manufacturing takes time

Collection, chain of identity, transport, manufacture, quality release, bridging treatment, and conditioning must be coordinated.

Early toxicity is serious

Cytokine-release syndrome, neurotoxicity, seizures, low blood pressure, infection, and prolonged cytopenias require specialist monitoring.

Follow-up lasts beyond discharge

The patient needs a caregiver, proximity to the center, blood counts, immune recovery, infection prevention, and long-term review.

Cost at a glance

Planning scenarios for car-t cell therapy in Thailand

The scenarios separate routine and complex pathways. They are not fixed packages and should be replaced by a report-led hospital estimate before travel.

Estimated car-t cell therapy cost scenarios in Thailand
Scenario	THB	USD	Patient and treatment context	Planning scope
Eligibility and collection work-up	THB 990,000 - 2,310,000	USD 30,000 - 70,000	Records, pathology, molecular or flow review, disease assessment, infection testing, vascular access, and leukapheresis planning before a product or trial decision.	Should state specialist review, tests, collection, cell transport or manufacturing assumptions, and what happens if the patient is not eligible.
Cellular-treatment program	THB 4,950,000 - 9,900,000	USD 150,000 - 300,000	An eligible patient accepted by a center and product pathway for lymphodepletion, CAR-T infusion, close monitoring, and planned admission.	Identify product, indication, manufacturing, lymphodepletion, infusion, caregiver, monitoring, and follow-up obligations.
Complex toxicity or prolonged course	THB 9,900,000 - 19,800,000+	USD 300,000 - 600,000+	Bridging treatment, delayed manufacturing, severe cytokine-release syndrome, neurotoxicity, infection, ICU, ventilation, transfusion, or prolonged recovery.	Use an explicit contingency for ICU, tocilizumab or equivalent supportive treatment, steroids, seizures, infection, and extra accommodation.

Usually included

Check the clinical package scope

Eligibility assessment

Cancer type, antigen or product indication, previous treatment, pathology, disease burden, performance status, organs, infection, and trial criteria.

The center must confirm acceptance in writing.

Cell collection pathway

Leukapheresis, vascular access, cell handling, identity checks, transport, manufacturing or trial-laboratory assumptions.

Failed or insufficient collection terms matter.

Conditioning and infusion

Lymphodepletion, product infusion, inpatient monitoring, laboratory tests, toxicity observation, and specialist review as listed.

Product and hospital lines should be separate.

Discharge and long follow-up

Caregiver education, blood counts, infection, immunoglobulin, vaccination, restrictions, emergency card, and cellular-therapy follow-up.

The patient cannot treat the discharge date as the end of care.

Confirm separately

Charges that may sit outside the range

Product access uncertainty

Trial screening, product registration, import, manufacturing slot, failed release, antigen mismatch, or ineligibility.

No deposit should imply guaranteed cell manufacture.

Bridging and disease control

Chemotherapy, radiation, steroids, transfusion, infection care, urgent admission, or another therapy while cells are prepared.

The disease may change during manufacturing.

ICU and toxicity care

Cytokine-release syndrome, neurotoxicity, seizures, ventilation, vasopressors, tocilizumab or equivalent support, steroids, and infection treatment.

Ask for ICU and daily overstay rates.

Long-term living costs

Caregiver, hotel near the center, transport restrictions, delayed flight, local laboratories, medicines, immunoglobulin, and home follow-up.

Plan a long recovery window.

Candidate context

Who may be considered and what else may be discussed

CAR-T may be considered for selected blood cancers when a product, clinical trial, or authorized pathway matches the diagnosis and the patient meets strict criteria. The center needs pathology, flow or molecular findings, antigen expression where relevant, previous lines, response, marrow or organ status, infection history, performance status, and treatment goals. Thailand’s national and academic sources describe CAR-T development and cellular-therapy expertise, but patients must distinguish research, trial, hospital-made, imported, and commercially available routes. A destination is not confirmed until the named center accepts the case and explains the product pathway.

Information that shapes suitability

Matching indication

The cancer, antigen, age range, prior lines, relapse or refractory status, and product criteria must match the center or trial.

Disease control before infusion

High disease burden may need bridging treatment, while rapid progression can make manufacturing or waiting unsafe.

Organ and infection reserve

Heart, lungs, kidney, liver, marrow, infection, neurologic history, and performance status influence eligibility and toxicity risk.

Manufacturing feasibility

Adequate collection, identity, chain of custody, manufacturing, quality release, and product timing must be realistic.

Caregiver and proximity

A responsible caregiver, nearby accommodation, emergency transport, language support, and several weeks of local availability are essential.

Alternatives or sequencing questions

Salvage chemotherapy or antibody treatment

A hematology team may use another systemic option to control disease while a product route is assessed or when CAR-T is unsuitable.

Stem-cell transplant

Autologous or allogeneic transplant can be an alternative for selected blood cancers after specialist evaluation.

Antibody or cellular trial

An antibody-drug, bispecific, NK-cell, or another investigational pathway may be available depending on the diagnosis and trial criteria.

Supportive and palliative care

Transfusion, infection treatment, pain, nutrition, symptom control, and goals-of-care support remain important at every stage.

Procedure variations

Why the named procedure does not have one price

Technique, device, medicine, treatment extent, and prior care can change both the clinical plan and the estimate.

Commercial product pathway

An authorized product is obtained, manufactured, released, and infused at a center meeting its requirements.

Verify local product registration and supply for the exact indication.

Clinical-trial pathway

Eligibility, protocol, sponsor, consent, trial visits, safety reporting, and possible research-specific costs apply.

Trial participation is not the same as buying a package.

Autologous collection

The patient’s T cells are collected, modified or prepared, tested, and returned after conditioning.

Chain of identity and failed-manufacture policy must be written.

Bridging treatment

Chemotherapy, radiation, steroid, or another therapy controls disease while cells are made or a slot is arranged.

Progression can change eligibility.

Post-infusion monitoring

The patient remains close for cytokine-release, neurologic, infection, blood-count, and organ monitoring.

Travel restrictions and caregiver obligations continue after discharge.

City comparison

Cost and capability by city in Thailand

Only cities with evidence for the procedure should appear here. A city range does not prove that every hospital in that city can manage the same case complexity.

Estimated car-t cell therapy costs and planning context by city in Thailand
City	Local range	USD range	Capability context	Stay planning
Bangkok	THB 1,320,000 - 19,800,000+	USD 40,000 - 600,000+	The strongest concentration of academic, cellular, hematology, ICU, research, and international coordination services.	Confirm product, trial or authorization, manufacturing, ICU, and long-term follow-up at the named center.
Chiang Mai	THB 1,155,000 - 13,200,000+	USD 35,000 - 400,000+	Academic hematology capability exists, while a CAR-T product or trial route requires direct center confirmation.	Ask whether collection and infusion are onsite or require Bangkok referral.
Phuket	THB 1,155,000 - 11,550,000+	USD 35,000 - 350,000+	International coordination is accessible, but advanced cellular manufacture and ICU depth cannot be assumed.	Do not select Phuket for convenience until a cell-therapy center accepts the case.
Pattaya and Chon Buri	THB 1,089,000 - 11,550,000+	USD 33,000 - 350,000+	Eastern hospitals may provide hematology or referral support rather than a full CAR-T pathway.	Confirm whether the named center can collect, manufacture, infuse, and manage toxicity.
Khon Kaen	THB 1,056,000 - 9,900,000+	USD 32,000 - 300,000+	Regional hematology expertise may support evaluation or bridging with tertiary referral.	Ask about transport of cells, trial screening, and Bangkok escalation.
Hat Yai and Songkhla	THB 1,056,000 - 9,900,000+	USD 32,000 - 300,000+	Southern services may support hematology assessment but advanced cellular access needs confirmation.	Do not split collection and infusion without a documented chain of identity.
Nakhon Ratchasima	THB 1,023,000 - 9,240,000+	USD 31,000 - 280,000+	Regional care may help with work-up and supportive treatment under a tertiary pathway.	Verify product, sponsor, center, and ICU rather than relying on an online price.
Chiang Rai	THB 990,000 - 8,250,000+	USD 30,000 - 250,000+	Evaluation may be available; full CAR-T delivery requires direct confirmation.	A safe referral and caregiver plan must be established before travel.
Udon Thani	THB 990,000 - 8,250,000+	USD 30,000 - 250,000+	Regional hematology and supportive services can be part of an assessment pathway.	Confirm where collection, product manufacture, infusion, and ICU occur.
Rayong	THB 1,023,000 - 9,900,000+	USD 31,000 - 300,000+	Eastern transport routes may support selected work-up and referral.	Travel convenience cannot replace an accredited cell-therapy program.

Estimate variables

What can change the final hospital cost

Product and access route

Commercial approval, clinical trial, imported product, academic manufacture, sponsor requirements, and indication determine availability and cost.

Ask for a named route, not a generic package.

Collection and manufacture

Leukapheresis, access, transport, chain of identity, manufacture, release testing, failed collection, and failed manufacture create major variation.

Request written contingency terms.

Bridging and conditioning

Disease control before infusion and lymphodepleting chemotherapy add drugs, scans, admission, and risk.

The disease can change while cells are prepared.

Toxicity and ICU

Cytokine-release syndrome, neurologic events, seizures, infection, cytopenia, organ injury, and ventilation can extend stay.

Compare ICU and specialist response capacity.

Long follow-up

Blood counts, immunoglobulin, infection prevention, vaccination, restrictions, caregiver, housing, and late monitoring continue after discharge.

Budget weeks, not a short visit.

Medical cost breakdown

Before admission, in hospital, and after discharge

Diagnostics and preparation

Eligibility evidence

Pathology, flow cytometry, molecular findings, antigen, prior treatment, response, marrow, and disease-burden assessment.

The center may repeat tests under its protocol.

Organ and infection work-up

CBC, kidney, liver, heart, lung, infection, pregnancy, neurologic, and performance-status assessment.

Uncontrolled infection may delay or prevent treatment.

Cell collection preparation

Vascular assessment, leukapheresis review, medication management, transfusion, imaging, and sponsor or trial screening.

Ask what happens if collection is inadequate.

Admission and treatment

Collection admission

Apheresis, vascular access, nursing, laboratory, cell handling, transport, and observation.

Collection is not the product infusion.

Conditioning and infusion

Lymphodepletion, cell infusion, pharmacy or manufacturing charges, inpatient monitoring, labs, and specialist rounds.

Confirm product and hospital charges separately.

Toxicity admission

Fever, cytokine-release, low blood pressure, oxygen, seizures, neurotoxicity, infection, transfusion, ventilation, or ICU.

This phase can dominate total cost.

Recovery and follow-up

Early cellular recovery

Blood counts, fever, blood pressure, oxygen, neurologic checks, infection, transfusion, and nutrition are followed closely.

A caregiver needs practical training.

Immune recovery

Immunoglobulin, infection prophylaxis, vaccination timing, antibiotic or antiviral treatment, and delayed cytopenia review.

The immune system may remain vulnerable.

Long-term monitoring

Disease response, marrow, blood count, late neurologic issues, secondary problems, restrictions, and specialist visits.

Plan home hematology follow-up.

Complete journey budget

Plan beyond the hospital invoice

Patient and attendant costs should be modeled separately from the medical estimate, with flexible dates and a contingency reserve.

Pre-travel evaluation

Pathology, flow, antigen, prior lines, trial criteria, organs, infections, caregiver, visa, insurance, and center acceptance.

Do not fly for a speculative package.

Manufacturing window

Collection, bridging treatment, repeat tests, housing near the center, transport limits, caregiver, and possible delayed infusion.

The timetable can move.

Post-infusion stay

Admission, nearby accommodation, emergency transport, labs, blood products, medicines, delayed flight, and home handover.

Follow the center’s travel restrictions.

Country access

Rules and practical requirements to verify

Visa, donor, fertility, medicine, licensing, and treatment-access requirements can change. Confirm current rules with the relevant authority and treating hospital.

Verify the exact route

Ask the Thai center whether the case is commercial, trial, research, imported, or another pathway and request the current authorization or sponsor information.

Confirm center and product

The named hospital should identify its cellular program, collection, manufacturing or partner laboratory, infusion location, ICU, and follow-up.

Review trial terms

Read eligibility, consent, sponsor costs, research procedures, withdrawal, adverse-event, insurance, and what happens after the trial.

Protect chain of identity

Confirm patient identity, labeling, transport, manufacturing release, privacy, failed product, cancellation, and return or disposal terms.

Use official travel guidance

Check Thailand e-Visa or embassy information and plan for a caregiver, prolonged stay, restricted travel, and delayed return.

Hospital selection

Compare capability before package price

Cell-therapy program

Hematology, cellular-therapy physician, apheresis, laboratory, pharmacy, transplant or ICU, infection, and emergency support.

A general oncology department is not enough.

Product legitimacy

Product name, antigen, indication, registration or trial number, sponsor, manufacturing site, release testing, and patient eligibility.

Ask for documentation before deposit.

Toxicity response

Cytokine-release, neurotoxicity, seizure, infection, cytopenia, transfusion, oxygen, vasopressor, ventilation, and ICU pathways.

Care depth must match the treatment.

Caregiver and proximity

Education, nearby lodging, transport, emergency contact, language support, and rules for leaving the city or country.

The caregiver is part of the plan.

Long-term follow-up

Blood count, immunoglobulin, infection, vaccination, disease response, late effects, and home hematology communication.

Get a written follow-up schedule.

Treating team

Specialists and support that may matter

Hematologist and cellular-therapy specialist

Confirms product eligibility, disease status, bridging plan, lymphodepletion, infusion, response, and toxicity decisions.

Apheresis and cell-processing team

Collects, labels, transports, manufactures or coordinates the cells, and documents chain of identity and release.

Cell-therapy pharmacist and nurse

Checks conditioning, product handling, infusion, supportive medicines, reaction monitoring, and caregiver education.

ICU, neurology, and infection specialists

Manage cytokine-release, blood pressure, oxygen, seizures, neurologic change, infection, transfusion, and organ failure.

Home hematology team

Continues counts, immunoglobulin, infection prevention, response, vaccination, restrictions, and urgent assessment after return.

Treatment timeline

From report review to return-home follow-up

Eligibility and center review

Send pathology, flow or molecular results, prior lines, response, scans, marrow, organ tests, infection history, and trial questions.

Acceptance and consent

The center explains product route, indication, risks, manufacturing, costs, caregiver obligations, and what happens if the patient is not eligible.

Collection and manufacturing

Leukapheresis, identity checks, cell transport or manufacture, release testing, and disease control during the waiting period occur.

Conditioning and infusion

Lymphodepletion is followed by the cell infusion and close inpatient monitoring under the center’s protocol.

Early toxicity window

Fever, blood pressure, oxygen, neurologic status, seizures, blood counts, infection, and organ function are assessed continuously.

Long follow-up

The patient remains near the center as instructed, then returns with a response, count, infection, medicine, caregiver, and emergency plan.

Risks and edge cases

Events that can change the plan, stay, or cost

Not eligible after review

Disease type, antigen, prior treatment, organ function, infection, performance status, or trial criteria may exclude the patient.

Do not treat a preliminary inquiry as acceptance.

Insufficient collection or failed manufacture

Apheresis, cell quality, transport, contamination, identity, or release issues can delay or cancel infusion.

Written refund and alternative terms matter.

Disease progression during wait

Bridging therapy may fail, symptoms can worsen, or the patient may no longer be fit for infusion.

Ask for an interim hematology plan.

Cytokine-release syndrome

Fever, low blood pressure, oxygen need, and organ stress may require specialist medicines, ward escalation, or ICU.

This is a treatment emergency.

Neurologic toxicity

Confusion, speech change, tremor, seizure, weakness, or reduced consciousness can need steroids, monitoring, and ICU.

The caregiver needs warning training.

Cytopenia and infection

Low counts, transfusion, viral or bacterial infection, fungal risk, and prolonged immune suppression can extend recovery.

Do not plan an early flight.

Destination comparison

Compare India, Turkey, and Thailand for this procedure

The most suitable destination depends on the individual case, required team, treatment availability, travel route, legal eligibility, budget, and continuity after returning home.

Procedure planning comparison across India, Turkey, and Thailand
Decision factor	India	Turkey	Thailand	How to use this
Cellular access	Growing academic and private cellular-therapy programs with product and trial variation.	Selected transplant and cellular programs with access depending on product and center.	Academic development and specialist cellular services exist, but CAR-T product and trial availability must be confirmed case by case.	Compare product legitimacy, trial terms, ICU, and follow-up rather than advertising language.
Cost structure	Product, manufacture, hospital, ICU, and supportive medicines may be separate.	Foreign-currency packages can hide product or complication assumptions.	THB planning ranges are broad because the route may be trial, imported, research, or product-specific.	Request a signed scope and failed-manufacture terms.
Regional care	Work-up or bridging may occur regionally, while infusion often clusters in specialist centers.	Specialist cellular access is concentrated in selected institutions.	Evaluation may be regional, but complex infusion and ICU are likely to cluster in major centers.	Do not split the chain without accountability.
Travel continuity	Practical for South Asian, Gulf, and African patients.	Practical for Europe, Gulf, and Central Asia.	Practical for Southeast Asia and Asian routes.	Caregiver, proximity, language, and restricted travel are central.

Decision guidance

When Thailand may fit and when to keep comparing

Thailand may fit when

A named cellular center confirms the product or trial route, accepts the eligibility file, explains manufacturing and toxicity, and provides long follow-up.

Keep comparing when

A website quotes a universal CAR-T price without naming the product, indication, center, sponsor, or authorization, or promises a guaranteed cure.

Regional work-up may fit when

A tertiary hematologist coordinates pathology, collection, bridging, transport, and referral to the infusion center.

Urgent local care comes first when

There is fever, low blood pressure, breathlessness, confusion, seizure, rapidly worsening blood counts, or uncontrolled disease.

Reports for review

Prepare a case file before requesting estimates

Prepare pathology, flow or molecular results, antigen evidence, prior treatments and responses, marrow, scans, blood counts, organs, infection tests, medicines, performance status, caregiver details, and trial questions. Ask the Thai center for a written proposal identifying product or trial, eligibility, collection, manufacturing, bridging, conditioning, infusion, ICU, caregiver, THB validity, failed-manufacture terms, and home follow-up.

Upload medical reports

Cell-therapy eligibility

Cancer diagnosis

Include histology, flow cytometry, molecular profile, antigen, stage, relapse or refractory status, and disease burden.

Treatment history

List every line, transplant, antibody, chemotherapy, radiation, response, progression date, and toxicity.

Organ and infection file

Provide marrow, blood, kidney, liver, heart, lung, infection, neurologic, and performance-status results.

Scans and marrow

Send PET, CT, MRI, marrow, pathology, and source images with dates for comparison.

Caregiver and travel file

Current medicines

List steroids, immunosuppressants, anticoagulants, antivirals, antibiotics, supplements, and allergies.

Caregiver plan

Name the caregiver, language, accommodation, transport, communication, emergency, and proximity arrangements.

Travel documents

Share passport, visa, insurance, companion, financial reserve, and flexible return information.

Home hematology

Identify the local hematologist, laboratory, blood bank, emergency hospital, and infection support.

Quote and trial questions

Product route

Ask whether the route is commercial, trial, research, imported, or academic and request product and sponsor documents.

Manufacturing

Confirm collection, chain of identity, transport, manufacture, release, failed product, and refund terms.

Toxicity

Request CRS, neurologic, ICU, infection, transfusion, and prolonged-stay assumptions.

Aftercare

Agree caregiver rules, restricted travel, blood counts, immunoglobulin, vaccination, response, and home handover.

Common questions

Questions about cost, travel, and follow-up

What is CAR-T cell therapy cost in Thailand?

Eligibility and collection work may be THB 990,000 to 2,310,000, while a full accessible program may be THB 4,950,000 to 9,900,000 and complex care can exceed THB 19,800,000.

Is CAR-T commercially available in Thailand?

Availability is product-, indication-, center-, and time-dependent. Official sources describe Thai development and specialist cellular work, so direct confirmation from the named center is essential.

Can any cancer patient receive CAR-T?

No. Diagnosis, antigen, prior lines, disease status, organ function, infection, performance status, and product or trial criteria determine eligibility.

What happens before the infusion?

The pathway may include pathology and eligibility review, leukapheresis, manufacturing, bridging treatment, lymphodepletion, and close planning with a caregiver.

What is cytokine-release syndrome?

It is an inflammatory reaction that can cause fever, low blood pressure, oxygen need, and organ stress and may require specialist treatment or ICU.

What is neurotoxicity?

Confusion, speech change, tremor, seizure, weakness, or reduced consciousness can occur and needs urgent cell-therapy assessment.

How long should I stay in Thailand?

The center sets the period for collection, manufacture, infusion, monitoring, caregiver proximity, blood counts, and travel restrictions; it is not a short package visit.

Can a regional city provide CAR-T?

A regional city may support evaluation or bridging, but collection, manufacture, infusion, and ICU must be confirmed at the exact center.

What if manufacture fails?

The contract should explain failed collection or release, refund, repeat collection, alternative treatment, and who manages disease progression.

What records should I send?

Send pathology, flow or molecular results, antigen, prior lines, scans, marrow, organs, infections, medicines, performance status, and caregiver plan.

Review and sources

How this guide was prepared

The ranges are deliberately broad because CAR-T access in Thailand is product-, center-, indication-, trial-, and time-dependent. They distinguish eligibility and collection work, a complete accessible program, and complex toxicity or prolonged care. The working conversion is approximately THB 33 per USD using the Bank of Thailand source checked in July 2026. Government and academic sources support a development and cellular-therapy context, not a universal commercial availability claim. The named center must provide the final scope, product, sponsor, and terms.

This page is educational and cannot establish CAR-T eligibility, product availability, trial enrollment, safety, or outcome. A hematology and cellular-therapy center must review the full record. Fever, low blood pressure, breathlessness, confusion, seizure, or rapidly worsening illness requires urgent local medical care.

Related planning